Tissue damage-associated "danger signals" influence T-cell responses that promote the progression of preneoplasia to cancer
about
Aggressiveness Niche: Can It Be the Foster Ground for Cancer Metastasis Precursors?Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophagesDamage-associated molecular patterns in cancer: a double-edged swordDistinct dendritic cell subsets dictate the fate decision between effector and memory CD8(+) T cell differentiation by a CD24-dependent mechanism.Emerging role of HMGB1 in lung diseases: friend or foe.The association of HMGB1 expression with clinicopathological significance and prognosis in hepatocellular carcinoma: a meta-analysis and literature review.HMGB1 in health and disease.DAMPs, ageing, and cancer: The 'DAMP Hypothesis'.The role of formyl peptide receptor 1 (FPR1) in neuroblastoma tumorigenesis.Life after death: targeting high mobility group box 1 in emergent cancer therapies.Many faces of DAMPs in cancer therapy.HMGB1 in cancer: good, bad, or both?Danger signalling during cancer cell death: origins, plasticity and regulation.Autoimmunity as a double agent in tumor killing and cancer promotion.TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells.HMGB1 in hormone-related cancer: a potential therapeutic target.Innate immunity for better or worse govern the allograft response.Siglec-G represses DAMP-mediated effects on T cells.Redirecting the focus of cancer immunotherapy to premalignant conditions.HMGB1: A Promising Therapeutic Target for Prostate Cancer.HMGB1: The Central Cytokine for All Lymphoid Cells.The adaptive immune system promotes initiation of prostate carcinogenesis in a human c-Myc transgenic mouse model.Post-translational modifications of high mobility group box 1 and cancer.Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses.Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy.Improvement of Antitumor Therapies Based on Vaccines and Immune-Checkpoint Inhibitors by Counteracting Tumor-Immunostimulation.Tumor-derived high-mobility group box 1 and thymic stromal lymphopoietin are involved in modulating dendritic cells to activate T regulatory cells in a mouse model.Current status of diagnosis and treatment of bladder cancer in China - Analyses of Chinese Bladder Cancer Consortium database.Role of nonresolving inflammation in hepatocellular carcinoma development and progression.High mobility group box 1 promotes the epithelial-to-mesenchymal transition in prostate cancer PC3 cells via the RAGE/NF-κB signaling pathway.Trial watch: Immunogenic cell death induction by anticancer chemotherapeuticsA novel function of API5 (apoptosis inhibitor 5), TLR4-dependent activation of antigen presenting cells
P2860
Q26738966-7050236E-5E31-4B03-A5B2-0B9692E55036Q27325462-E071DE72-B995-4993-AE27-4457B00A188CQ28067434-47D507AD-FD0D-4C42-9E76-6544371DE754Q30407392-836B9385-27BE-438B-A0A4-F2C629286728Q33684145-88E6FE47-A9D8-4030-8767-FCC109F86104Q34428389-181764B1-30D4-42E8-BF13-B84B0A7E8CFDQ34622835-60900B68-57F2-440E-BA4E-D3824C3D7A05Q35558632-BBD68612-6421-49EA-BD8D-D9F880B0821CQ36081204-BBC06E88-0D86-4659-A2CB-A761EA171B44Q36562901-3344CA19-094E-4986-9413-D349FEAA5E23Q36907117-E9A5BE8E-5B8A-4CF2-9A0C-2E06881605F0Q37067481-539087C8-A90B-4992-B90F-7EA7EB36BBBEQ37381745-7CE6DE44-4911-46D0-8594-DD9E86D912FAQ37642271-2ABD6382-BD1F-4A95-A64A-962856BA3662Q37729984-4BCA31AC-57EE-4488-BF96-C54E0F62A638Q38203471-4D9319B9-5A56-4E67-9F92-37D8536A59B8Q38309267-735B8035-B87E-4BFE-81A5-DA7BD26FBB89Q38671407-02D0403F-F48F-4955-A105-1DF935667424Q39107022-91B569F8-778B-4FB9-B537-83DF4FF3BADCQ41136849-1D73B08B-E20F-4A58-9E6B-F838E3080613Q43224085-A2D8C50F-D4D2-472C-B835-C60F954EF913Q47163967-3C8506C9-09D9-4416-9E43-BDF29ED68780Q47220872-4C7A7A77-2BDB-405A-8512-347A880576EEQ47614555-A9EB3BC9-683E-4C57-BB68-065C8F7DD28FQ47681122-2B915B58-0C4A-49DD-95F9-277EA979138DQ49872011-9D319A56-D219-4B3E-AF54-AF0987BD500EQ50109080-4331126A-CFAF-4043-9FDB-9C81648E6D34Q53073693-EEF079F6-E4AA-4778-BCD1-A3E0BF161E2FQ55288642-8AD1B453-FA21-4B7A-B61F-AA3B66A6CD0BQ55307923-A44BFFA7-087E-46CA-A5BE-E8D033218496Q56594845-B9E921D8-9B4C-4275-A699-ECD592430D8AQ57133698-76251AA4-3810-4667-92D1-8772BD59BF78
P2860
Tissue damage-associated "danger signals" influence T-cell responses that promote the progression of preneoplasia to cancer
description
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2013
@ast
im Januar 2013 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2013/01/15)
@sk
vědecký článek publikovaný v roce 2013
@cs
wetenschappelijk artikel (gepubliceerd op 2013/01/15)
@nl
наукова стаття, опублікована в січні 2013
@uk
مقالة علمية (نشرت في 15-1-2013)
@ar
name
Tissue damage-associated "dang ...... sion of preneoplasia to cancer
@ast
Tissue damage-associated "dang ...... sion of preneoplasia to cancer
@en
Tissue damage-associated "dang ...... sion of preneoplasia to cancer
@nl
type
label
Tissue damage-associated "dang ...... sion of preneoplasia to cancer
@ast
Tissue damage-associated "dang ...... sion of preneoplasia to cancer
@en
Tissue damage-associated "dang ...... sion of preneoplasia to cancer
@nl
prefLabel
Tissue damage-associated "dang ...... sion of preneoplasia to cancer
@ast
Tissue damage-associated "dang ...... sion of preneoplasia to cancer
@en
Tissue damage-associated "dang ...... sion of preneoplasia to cancer
@nl
P2093
P3181
P1433
P1476
Tissue damage-associated "dang ...... sion of preneoplasia to cancer
@en
P2093
P304
P3181
P356
10.1158/0008-5472.CAN-12-2704
P407
P577
2012-10-29T00:00:00Z